Equities analysts expect that Alkermes PLC (NASDAQ:ALKS) will announce $239.12 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Alkermes’ earnings, with the highest sales estimate coming in at $241.10 million and the lowest estimate coming in at $237.50 million. Alkermes reported sales of $213.51 million during the same quarter last year, which indicates a positive year over year growth rate of 12%. The firm is expected to report its next quarterly earnings report on Wednesday, February 21st.

According to Zacks, analysts expect that Alkermes will report full-year sales of $239.12 million for the current fiscal year, with estimates ranging from $852.40 million to $889.00 million. For the next fiscal year, analysts expect that the firm will report sales of $974.46 million per share, with estimates ranging from $886.40 million to $1.07 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Alkermes.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Thursday, October 26th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.04. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The company had revenue of $217.40 million for the quarter, compared to the consensus estimate of $231.29 million. During the same quarter last year, the company earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 20.6% compared to the same quarter last year.

Several analysts have recently commented on ALKS shares. BidaskClub downgraded shares of Alkermes from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. Jefferies Group set a $69.00 target price on shares of Alkermes and gave the company a “buy” rating in a research note on Friday, August 25th. ValuEngine raised shares of Alkermes from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Barclays downgraded shares of Alkermes from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $66.00 to $50.00 in a research note on Monday, October 16th. Finally, Mizuho set a $81.00 target price on shares of Alkermes and gave the stock a “buy” rating in a report on Saturday, October 21st. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $63.55.

In other Alkermes news, SVP James M. Frates sold 20,932 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $50.51, for a total value of $1,057,275.32. Following the completion of the sale, the senior vice president now owns 164,971 shares of the company’s stock, valued at $8,332,685.21. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard F. Pops sold 50,000 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $48.87, for a total value of $2,443,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 121,930 shares of company stock worth $5,999,130 in the last three months. Corporate insiders own 5.34% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC raised its position in Alkermes by 0.4% in the second quarter. FMR LLC now owns 22,978,575 shares of the company’s stock valued at $1,332,068,000 after purchasing an additional 96,457 shares during the period. Vanguard Group Inc. boosted its position in shares of Alkermes by 3.7% in the 2nd quarter. Vanguard Group Inc. now owns 12,546,198 shares of the company’s stock valued at $727,303,000 after purchasing an additional 449,563 shares during the period. Woodford Investment Management Ltd boosted its position in shares of Alkermes by 2.4% in the 2nd quarter. Woodford Investment Management Ltd now owns 7,647,977 shares of the company’s stock valued at $443,353,000 after purchasing an additional 177,449 shares during the period. Thornburg Investment Management Inc. raised its stake in Alkermes by 39.8% during the 3rd quarter. Thornburg Investment Management Inc. now owns 2,779,364 shares of the company’s stock valued at $141,303,000 after acquiring an additional 790,692 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in Alkermes by 13.7% during the 3rd quarter. Janus Henderson Group PLC now owns 2,650,006 shares of the company’s stock valued at $134,726,000 after acquiring an additional 319,014 shares during the last quarter. 99.75% of the stock is currently owned by institutional investors.

Alkermes (NASDAQ:ALKS) opened at $52.29 on Friday. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23. Alkermes has a 1-year low of $46.42 and a 1-year high of $63.40.

TRADEMARK VIOLATION WARNING: “Zacks: Analysts Anticipate Alkermes PLC (ALKS) Will Announce Quarterly Sales of $239.12 Million” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/01/zacks-analysts-anticipate-alkermes-plc-alks-will-announce-quarterly-sales-of-239-12-million.html.

About Alkermes

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Get a free copy of the Zacks research report on Alkermes (ALKS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.